How Nuclear Cardiology Transformed Patient Care in Cardiac Amyloidosis, and What the Remarkable Developments in the Field Have Taught Us Developments have unfolded in cardiac amyloidosis, ... where we ...
Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.
The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has added ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of ...
Cardiac amyloidosis is a rare condition defined by the abnormal production of proteins that bind together to form amyloid proteins. These amyloids can gather in different organs throughout the body, ...
Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA ...
The American Society of Hematology (ASH) released guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening disease of the bone marrow. The guidelines, published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results